Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes

Journal of Hypertension

Volumn 23, Issue 3, 2005, Pages 463-473

  Jandeleit Dahm, Karin A M ^a   Tikellis, Christos ^a   Reid, Christopher M ^a   Johnston, Colin I ^a   Cooper, Mark E ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Diabetes; Hypertension; Pancreatic cells

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; GLUCOSE; HYDROCHLOROTHIAZIDE; INSULIN; LISINOPRIL; LOSARTAN; PLACEBO; RAMIPRIL; RENIN; VALSARTAN;

ANIMAL MODEL; APOPTOSIS; ATTENUATION; CELL DEATH; CLINICAL TRIAL; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG DOSE REGIMEN; DRUG MECHANISM; GLUCOSE TRANSPORT; HEMODYNAMICS; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INCIDENCE; INSULIN METABOLISM; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SYNTHESIS; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PANCREATITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SYSTEMATIC REVIEW; UPREGULATION; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 18844449196     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000160198.05416.72     Document Type: Review

References (86)

1. Cooper ME, Johnston CI. Optimizing treatment of hypertension in patients with diabetes. JAMA 2000; 283:3177-3179.
2. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37:1053-1059.
3. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342:905-912.
4. Jandeleit-Dahm K, Cooper ME. Hypertension diabetes. Curr Opin Nephrol Hypertens 2002; 11:221-228.
5. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355:253-259.
6. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
7. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-788.
8. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041.
9. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 2002; 20:2099-2110.
10. McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003; 91:30H-37H.
11. Kahn SE, Andrikopoulos S, Verchere CB. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 1999; 48:241-253.
12. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611-616.
13. Niklason A, Hedner T, Niskanen L, Lanke J. Development of diabetes is retarded by ACE inhibition in hypertensive patients - a subanalysis of the Captopril Prevention Project (CAPPP). J Hypertens 2004; 22:645-652.
14. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001; 38:E28-E32.
15. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-592.
16. Reid CM, Jonston CI, Ryan P, Willson K, Wing LM. Diabetes and cardiovascular outcomes in elderly subjects treated with ACE-inhibitors or diuretics: findings from the 2nd Australian National Blood Pressure Study. Am J Hypertens 2003; 16:A11.
17. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107:1291-1296.
18. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
20. Jones DW, Hall JE. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials. Hypertension 2004; 43:1-3.
21. Punzi HA, Punzi CF. Metabolic issues in the antihypertensive and lipid-lowering heart attack trial study. Curr Hypertens Rep 2004; 6:106-110.
22. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43:963-969.
23. Bakris GL, Sowers JR. When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk. Hypertension 2004; 43:941-942.
24. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20:1879-1886.
25. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362:759-766.
26. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767-771.
27. Unger T. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program. Am J Cardiol 2003; 91:28G-34G.
28. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21:1563-1574.
29. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B. Ramipril and the development of diabetes. JAMA 2001; 286:1882-1885.
30. Thamer M, Ray NF, Taylor T. Association between antihypertensive drug use and hypoglycemia: a case-control study of diabetic users of insulin or sulfonylureas. Clin Ther 1999; 21:1387-1400.
31. Velasquez MT, Bhathena SJ, Striffler JS, Thibault N, Scalbert E. Role of angiotensin-converting enzyme inhibition in glucose metabolism and renal injury in diabetes. Metabolism 1998; 47:7-11.
32. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321:868-873.
33. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317:713-720.
34. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14:173-194.
35. Kon V, Jabs K. Angiotensin in atherosclerosis. Curr Opin Nephrol Hypertens 2004; 13:291-297.
36. Jauch KW, Hartl W, Guenther B, Wicklmayr M, Rett K, Dietze G. Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin- dependent diabetes mellitus. Eur J Clin Invest 1987; 17:448-454.
37. Torlone E, Rambotti AM, Perriello G, Botta G, Santeusanio F, Brunetti P, Bolli GB. ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension. Diabetologia 1991; 34:119-125.
38. Shamiss A, Carroll J, Peleg E, Grossman E, Rosenthal T. The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM. Am J Hypertens 1995; 8:276-281.
39. Suzuki M, Ikebuchi M, Yokota C, Shinozaki K, Harano Y. Normalization of insulin resistance in non-obese essential hypertension by cilazapril treatment. Clin Exp Hypertens 1995; 17:1257-1268.
40. Shieh SM, Sheu WH, Shen DD, Fuh MM, Jeng CY, Jeng JR, et al. Improvement in metabolic risk factors for coronary heart disease associated with cilazapril treatment. Am J Hypertens 1992; 5:506-510.
41. Paolisso G, Gambardella A, Verza M, D'Amore A, Sgambato S, Varricchio M. ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 1992; 6:175-179.
42. Morel Y, Gadient A, Keller U, Vadas L, Golay A. Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol. J Cardiovasc Pharmacol 1995; 26:306-311.
43. Lender D, Arauz-Pacheco C, Breen L, Mora-Mora P, Ramirez LC, Raskin P. A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens 1999; 12:298-303.
44. Gans RO, Bilo HJ, Nauta JJ, Popp-Snijders C, Heine RJ, Donker AJ. The effect of angiotensin-I converting enzyme inhibition on insulin action in healthy volunteers. Eur J Clin Invest 1991; 21:527-533.
45. Heise T, Heinemann L, Kristahn K, Berger M, Sawicki PT. Insulin sensitivity in patients with essential hypertension: no influence of the ACE inhibitor enalapril. Horm Metab Res 1999; 31:418-423.
46. Petrie JR, Morris AD, Ueda S, Small M, Donnelly R, Connell JM, Elliott HL Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: a double-blind, placebo-controlled crossover trial. J Clin Endocrinol Metab 2000; 85:1882-1889.
47. Heinemann L, Heise T, Ampudia J, Sawicki P, Sindelka G, Brunner G, Starke AA. Four week administration of an ACE inhibitor and a cardioselective beta-blocker in healthy volunteers: no influence on insulin sensitivity. Eur J Clin Invest 1995; 25:595-600.
48. Reaven GM, Clinkingbeard C, Jeppesen J, Maheux P, Pei D, Foote J, et al. Comparison of the haemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens 1995; 8:461-466.
49. Henriksen EJ, Jacob S. Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance. Diabetes Obes Metab 2003; 5:214-222.
50. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 2004; 53:989-997.
51. Jacob S, Henriksen EJ, Fogt DL, Dietze GJ. Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle. Metabolism 1996; 45:535-541.
52. Miyata T, Taguchi T, Uehara M, Isami S, Kishikawa H, Kaneko K, et al. Bradykinin potentiates insulin-stimulated glucose uptake and enhances insulin signal through the bradykinin B2 receptor in dog skeletal muscle and rat L6 myoblasts. Eur J Endocrinol 1998; 138:344-352.
53. Dietze GJ, Wicklmayr M, Rett K, Jacob S, Henriksen EJ. Potential role of bradykinin in forearm muscle metabolism in humans. Diabetes 1996; 45(suppl 1):S110-S114.
54. Rett K, Wicklmayr M, Dietze GJ, Haring HU. Insulin-induced glucose transporter (GLUT1 and GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin. Diabetes 1996; 45(suppl 1):S66-S69.
55. Mitchell D, Tyml K. Nitric oxide release in rat skeletal muscle capillary. Am J Physiol 1996; 270:H1696-H1703.
56. Higashiura K, Ura N, Miyazaki Y, Shimamoto K. Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension. J Hum Hypertens 1999; 13(suppl 1):S71-S74.
57. Folli F, Saad MJ, Velloso L, Hansen H, Carandente O, Feener EP, Kahn CR. Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes 1999; 107:133-139.
58. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001; 38:884-890.
59. Dal Ponte DB, Fogt DL, Jacob S, Henriksen EJ. Interactions of captopril and verapamil on glucose tolerance and insulin action in an animal model of insulin resistance. Metabolism 1998; 47:982-987.
60. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356:359-365.
61. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-1756.
62. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-372.
63. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Hypertension 1999; 34:1129-1133.
64. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist versus a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805-2816.
65. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Pettiti M, Natali A, et al. Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. Diabetologia 2003; 46:1211-1219.
66. Carlsson PO, Berne C, Jansson L, Angiotensin. II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998; 41:127-133.
67. Tahmasebi M, Puddefoot JR, Inwang ER, Vinson GP. The tissue renin-angiotensin system in human pancreas. J Endocrinol 1999; 161:317-322.
68. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002; 51:3274-3282.
69. Barton M, Carmona R, Ortmann J, Krieger JE, Traupe T. Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. Int J Biochem Cell Biol 2003; 35:826-837.
70. Kuno A, Yamada T, Masuda K, Ogawa K, Sogawa M, Nakamura S, et al. Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology 2003;124:1010-1019.
71. Ko SH, Kwon HS, Kim SR, Moon SD, Ahn YB, Song KH, et al. Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats. Biochem Biophys Res Commun 2004; 316:114-122.
72. Gilbert RE, Wilkinson-Berka JL, Johnson DW, Cox A, Soulis T, Wu LL, et al. Renal expression of transforming growth factor-beta inducible gene-h3 (beta ig-h3) in normal and diabetic rats. Kidney Int 1998; 54:1052-1062.
73. Gilbert RE, Kelly DJ, Cox AJ, Wilkinson-Berka JL, Rumble JR, Osicka T, et al. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000; 43:1360-1367.
74. Tikellis C, Cooper ME, Twigg SM, Burns WC, Tolcos M. Connective tissue growth factor is up-regulated in the diabetic retina: amelioration by angiotensin-converting enzyme inhibition. Endocrinology 2004; 145:860-866.
75. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003; 52:581-587.
76. Oliveira HR, Verlengia R, Carvalho CR, Britto LR, Curi R, Carpinelli AR. Pancreatic beta-cells express phagocyte-like NAD(P)H oxidase. Diabetes 2003; 52:1457-1463.
77. Cai H, Li Z, Dikalov S, Holland SM, Hwang J, Jo H, et al. NAD (P)H oxidase-derived hydrogen peroxide mediates endothelial nitric oxide production in response to angiotensin II. J Biol Chem 2002; 277:48311-48317.
78. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74:1141-1148.
79. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 2002; 61:186-194.
80. Miyata T. Alterations of non-enzymatic biochemistry in uremia, diabetes, and atherosclerosis ('carbonyl stress'). Bull Mem Acad R Med Belg 2002; 157:189-198.
81. Prisant LM. Preventing type II diabetes mellitus. J Clin Pharmacol 2004; 44:406-413.
82. Gerstein HC. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev 2002; 18(suppl 3):S82-S85.
83. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002; 89:18A-26A.
84. World Health Organization. Diabetes mellitus: Report of a WHO Study Group. Technical Report Series No. 727. Geneva, WHO; 1985.
85. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183-1197.
86. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-553.